Cosibelimab is a monoclonal antibody commercialized by Checkpoint Therapeutics, with a leading Pre-Registration program in Cutaneous Squamous Cell Carcinoma (cSCC). According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Cosibelimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The revenue for Cosibelimab is expected to reach an annual total of $388 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Cosibelimab Overview
Cosibelimab is under development for the treatment of hematological malignancies and solid tumor including endometrial cancer, colorectal cancer, small-cell lung cancer, malignant pleural mesothelioma, head and neck cancer, advanced cutaneous squamous cell carcinoma, metastatic melanoma, metastatic Merkel cell carcinoma, ureter cancer, bladder cancer, urethral cancer, oral cavity (mouth) cancer, pharyngeal neoplasm, laryngeal cancer, renal cell carcinoma and metastatic transitional carcinoma of the urothelium. It is administered by intravenous route. The drug candidate is a fully humanized antibody which acts by targeting PD-L1.
It was also under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma, metastatic non-small cell lung cancer, metastatic non-squamous non-small cell lung cancer, blood cancer, hodgkin lymphoma (B-cell hodgkin lymphoma), relapsed and refractory chronic lymphocytic leukemia (CLL).
Checkpoint Therapeutics Overview
Checkpoint Therapeutics (Checkpoint), a subsidiary of Fortress Biotech Inc, is a biotechnology company. It focuses on immunotherapy and targeted oncology for solid tumor cancers. The company’s lead product candidate, cosibelimab, an anti-PD-L1 antibody is undergoing a Phase 1 clinical trial for patients with cutaneous squamous cell carcinoma (CSCC). Checkpoint is developing olafertinib, a third-generation EGFR inhibitor for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The company is also advancing CK-302, an anti-GITR monoclonal antibody, CK-103, a small-molecule BET inhibitor, and an anti-CAIX antibody targeting renal cell carcinoma, all designed to enhance anti-tumor responses. Checkpoint is headquartered in Waltham, Massachusetts, the US.
The company reported revenues of (US Dollars) US$0.1 million for the fiscal year ended December 2023 (FY2023), a decrease of 46.4% over FY2022. The operating loss of the company was US$52.2 million in FY2023, compared to an operating loss of US$58.3 million in FY2022. The net loss of the company was US$51.9 million in FY2023, compared to a net loss of US$62.6 million in FY2022.
For a complete picture of Cosibelimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
